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Abstract
Background: The primary aim of this study is to assess, using individual participant data (IPD) meta-analysis, the
effects of administration of antenatal magnesium sulphate given to women at risk of preterm birth on important
clinical outcomes for their child such as death and neurosensory disability. The secondary aim is to determine
whether treatment effects differ depending on important pre-specified participant and treatment characteristics,
such as reasons at risk of preterm birth, gestational age, or type, dose and mode of administration of magnesium
sulphate.
Methods
Design: The Antenatal Magnesium Individual Participant Data (IPD) International Collaboration: assessing the
benefits for babies using the best level of evidence (AMICABLE) Group will perform an IPD meta-analysis to answer
these important clinical questions.
Setting/Timeline: The AMICABLE Group was formed in 2009 with data collection commencing late 2010.
Inclusion Criteria: Five trials involving a total 6,145 babies are eligible for inclusion in the IPD meta-analysis.
Primary study outcomes: For the infants/children: Death or cerebral palsy. For the women: Any severe maternal
outcome potentially related to treatment (death, respiratory arrest or cardiac arrest).
Discussion: Results are expected to be publicly available in 2012.
Keywords: Preterm birth, Magnesium sulphate, Individual patient data, Cerebral palsy, Meta-analysis
Background
Preterm birth and neurological outcome: The burden of
disease
Babies born preterm compared with those born at term
h a v eah i g h e rc h a n c eo fd y i n gi nt h ef i r s tf e ww e e k so f
life. Babies who survive have a greater risk of neurologic
impairment, such as cerebral palsy, blindness, deafness,
or cognitive dysfunction (either intellectual impairment
or developmental delay), and a greater risk of substantial
disability as a result of these neurologic impairments
[1,2]. Moreover, as the rate of preterm birth in many
countries has been rising, now up to 13% in the United
States [3] and 8% in Australia [4], more babies are at
risk of death and adverse neurological outcomes. Cere-
bral palsy and cognitive dysfunction are the most fre-
quent neurologic impairments, and any therapy that can
reduce their prevalence would have a substantial effect
on reducing overall neurologic impairments and disabil-
ities in surviving preterm infants.
Cerebral palsy is a term which includes a number of
different diseases or conditions that can arise at any
time during brain development. Cerebral palsy involves
a disorder of movement or posture, or both, and a dis-
order of motor function which is permanent but may
change over time [5]. The cerebral palsies remain the
most frequent cause of severe motor disability in
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thousand live births [5]. Over 90% of affected children
with cerebral palsy are expected to survive to 20 years
of age [6], contributing substantially to the burden of
illness into adulthood.
Very preterm birth (less than 32 weeks’ gestation) and
very low birthweight (less than 1500 g) are principal risk
factors for cerebral palsy [7,8], responsible for between
17% to 32% of all cases of cerebral palsy.
Evidence from population-based registries generally
shows increasing rates of cerebral palsy as gestational
age decreases; with overall rates of cerebral palsy now
generally considered to be stable over time [9-11] or
decreasing [12]. Intraventricular haemorrhage (IVH) is a
known risk factor for the later development of cerebral
palsy [13,14] with the rates of IVH and periventricular
leukomalacia, another risk for cerebral palsy, increasing
the earlier the gestational age at birth.
Biological plausibility and early evidence for effect of
antenatal use of magnesium sulphate on
neurodevelopment
In humans, magnesium is essential for key cellular pro-
cesses, including glycolysis, oxidative phosphorylation,
protein synthesis, DNA and RNA aggregation and main-
t e n a n c eo fp l a s m am e m b r a n ei n t e g r i t y[ 1 5 - 1 7 ] .M a g n e -
sium favourably affects mechanisms implicated in cell
death by decreasing proinflammatory cytokines or free
radicals produced during hypoxic-ischaemic reperfusion
and inflammatory diseases of pregnancy [15,18]. Magne-
sium prevents excitotoxic calcium-induced injury [19], by
a non-competitive voltage-dependent inhibition of the N-
methyl-D-aspartate receptor to glutamate which reduces
calcium entry into the cell [20]. Magnesium has some
beneficial haemodynamic effects including stabilising
blood pressure during the first two days of life in preterm
neonates [21], and may increase cerebral blood flow by
reducing constriction of the cerebral arteries [22].
Transplacental transfer of magnesium is rapid with mag-
nesium concentrations increased in fetal serum within one
hour of maternal intravenous administration [23].
The first report that antenatal magnesium sulphate
w a sa s s o c i a t e dw i t har e d u c e dr i s ko fI V H ,f r o m1 8 . 9 %
to 4.4%, in very low birth weight babies (less than 1500
g) came in 1992 [13] followed by a case-control analysis
from the California Cerebral Palsy project investigating
whether in utero exposure to magnesium sulphate was
associated with a lower prevalence of cerebral palsy in
low birth weight infants [24]. Cases were children with
cerebral palsy who were singletons and whose birth-
weight had been less than 1500 g. Controls were ran-
domly sampled from live births of less than 1500 g from
the same birth populations. Magnesium sulphate given
to the mother during labour was associated with a
dramatic reduction in the risk of cerebral palsy (odds
ratio 0.14; 95% confidence interval (CI) 0.05 to 0.51).
Other observational studies have supported a reduc-
tion in cerebral palsy in preterm babies after maternal
administration of magnesium sulphate [25-27] and some
have found a reduction in the risk of IVH [25,28] and
perinatal mortality [29]. However, not all observational
studies have reported benefit on the risk of IVH for
antenatal magnesium sulphate [30-32], cerebral palsy
[31,33,34], or perinatal mortality [30].
Magnesium sulphate, by its peripheral vasodilator effects
when infused intravenously, produces a sensation of
warmth, flushing and sweating. Reported maternal side-
effects, related to dosage and speed of infusion, include
nausea, vomiting, headache and palpitations. Magnesium
sulphate also acts as a neuromuscular blocking agent that
causes abolition of tendon reflexes [35]. Magnesium could
aggravate the cardiovascular or neuromuscular side-effects
of other drugs such as betamimetics, calcium-channel
blockers, digitalis and gentamicin. Infusion to concentra-
tions above the recommended therapeutic range can lead
to respiratory depression, respiratory arrest, cardiac arrest
and death. For the neonate, hypermagnesaemia can lead
to hyporeflexia, poor sucking, and, rarely, respiratory
depression needing mechanical ventilation [36,37].
Summary of the Cochrane systematic review (aggregate
data)
The Cochrane systematic review assessing the use of mag-
nesium sulphate for women at risk of preterm birth for
neuroprotection of the fetus [38] includes five trials (6145
babies): two from the US; the MagNet Trial [39] and the
Beam Trial [40], one from Australia and New Zealand; the
ActoMgSo4 Trial [41], one from France; the PreMag Trial
[42], and one that was worldwide, but predominantly from
developing countries; the Magpie Trial [43]. The first four
trials specifically targeted women likely to give birth early
and magnesium was used for neuroprotection, although
one study, the MagNet trial [39], also had a tocolytic arm.
The fifth study, the Magpie Trial was designed to prevent
eclampsia in women with pre-eclampsia and included
women at all gestational ages. Data from the Magpie Trial
study relevant to women randomised before birth and at
less than 37 weeks were provided by the authors for inclu-
sion in the Cochrane review.
There was diversity in the inclusion and exclusion cri-
teria for the five included trials. In particular there was
a wide variation in reasons women were at risk of pre-
term birth (preterm labour, preterm prelabour rupture
of the membranes, pre-eclampsia), the gestational age
women were eligible, time of treatment prior to
expected preterm birth and drug regimens (Table 1).
Paediatric mortality was reported in five trials with
6145 babies. Antenatal magnesium sulphate treatment
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tality overall (risk ratio (RR) 1.04, 95% CI 0.82 to 1.17,
five trials, 6145 infants). While results between treat-
ment intent did not differ, there was substantial hetero-
geneity (I
2 = 45%) between studies for this outcome,
largely due to the other intent (tocolytic) arm of the
MagNet study (RR 15.8, 95% CI 0.93 to 267, 106
infants).
Cerebral palsy was reported in five trials with 6145
infants. There was a 32% relative reduction in risk of
cerebral palsy with antenatal magnesium sulphate treat-
ment, (overall RR 0.68, 95% CI 0.54 to 0.87). This
remained significant within the neuroprotective intent
group (RR 0.71, 95% CI 0.55 to 0.91, four trials, 4446
infants). Overall, the number needed to treat to prevent
one case of cerebral palsy was 63 (95% CI 39 to 172).
Antenatal magnesium sulphate treatment had no over-
all significant effect on the combined outcome of pae-
diatric mortality or cerebral palsy, but there was
substantial heterogeneity overall (I
2 = 51.3%). However,
there was a significant reduction in the combined out-
come of paediatric mortality or cerebral palsy in the
neuroprotection subgroup (RR 0.85, 95% CI 0.74 to
0.98, four trials, 4446 infants), with little evidence of
heterogeneity (I
2 = 5.3%). The number needed to treat
for an extra survivor free of cerebral palsy in the neuro-
protective subgroup was 41 (95% CI 22 to 357).
Need for an individual participant data meta-analysis
Aggregate data analysis methods such as those used in
the Cochrane review are limited because, for example,
results for women with different levels of risk have been
averaged, potentially concealing any different effects by
reasons that women were considered to be at risk for
preterm birth. Similarly wide within-trial variation in
different degrees of effect of magnesium sulphate by
gestational age is concealed by aggregation. Aggregated
outcomes such as ‘the number of children developing
cerebral palsy’ i n c l u d ear a n g eo fs e v e r i t yo ft h ed i s o r -
der. The published aggregate data is variable in comple-
teness of reporting outcomes and in the definitions used
within the trials. Not all trials have published the same
combined outcomes and very few subgroup analyses
using similar subgroup categories (such as gestational
age) have been published, making aggregation of these
results impossible.
Many questions remain. Is antenatal magnesium sul-
phate treatment more effective in some women by rea-
son of their risk of preterm birth? What is the
gestational age range for maximal benefit? What dose
and timing prior to birth of magnesium is best? Is main-
tenance treatment or re-treatment necessary?
The best way to address the limitations of the aggre-
gate meta analysis is to use the large amount of existing
trial data and conduct an individual participant data
(IPD) review and meta-analysis, rather than undertake
another trial which would need to be much larger than
any of the existing trials to be able to address the multi-
ple subgroup analyses with sufficient power.
Analysis of thoroughly checked and updated data from
individual participants in all the available randomised
trials has been described as the gold standard in sys-
tematic reviews [44]. Estimates of treatment effects are
often different from those obtained from aggregate pub-
lished data due to the ability to include additional
unpublished data and to categorise all participants
according to standardised definitions. The methods and
advantages of IPD review have been well described
[45,46].
Advantages that address the limitations of aggregate
data analyses reported include the ability to:
￿ undertake subgroup analyses to examine important
hypotheses about differences in treatment effect that
cannot be achieved with the published aggregate data,
Table 1 Eligible trials with their inclusion criteria and magnesium regimens as at September 2011
Trial GA at
entry
(weeks)
Treatment intent Magnesium sulphate regimen Comparator
Mittendorf 2002 [39] 25 to 33 Tocolysis (cervical dilatation
< 4 cm) or;
4 g bolus followed by 2 to 3 g/hour maintenance Alternative
tocolytic
Neuroprotection of the fetus/
infant/child (dilatation ≥ 4 cm)
4 g bolus (no repeats) Placebo
Rouse 2008 [40] 24 to 32 Neuroprotection of the fetus/
infant/child
6 g over 20-30 mins followed by 2 g/hr (retreatment
permitted)
Placebo
Crowther 2003 [41] less than
30
Neuroprotection of the fetus/
infant/child
4 g over 20 mins, then 1 g/hour for up to 24 hours or
birth (no repeats)
Placebo
Marret 2008 [42] less than
33
Neuroprotection of the fetus/
infant/child
4 g (no repeats) Placebo
The Magpie Trial
Collaborative Group 2002
[43]
less than
37
Neuroprotection of the
pre-eclamptic mother
4 g over 10-15 mins, then either 1 g/hour for 24 hours,
or 5 g every 4 hours IM for 24 hours (no repeats)
Placebo
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pant-level characteristics,
￿ collect uniformly defined, relevant data for all trials.
An integral component of conducting this IPD meta-
analysis is the formation of an international collabora-
tive group of trialists where all researchers endorse the
IPD protocol and provide data from their trials. This
generates additional benefits that include:
￿ more complete identification of trials and of trial
details,
￿ compliance with standard definitions, provision of
missing data on characteristics of trials, all women who
were randomised and their babies, and outcomes,
￿ more balanced interpretation, endorsement and glo-
bal dissemination of results, and
￿ better clarification and consensus on future research
needed with the opportunity for ongoing international
collaborations.
Objectives
To assess, using IPD meta-analyses, the effects of
administration of antenatal magnesium sulphate given
to women at risk of preterm birth on important clinical
outcomes, and whether treatment effects differ depend-
ing on important prespecified participant and treatment
characteristics:
￿ the reason the woman was considered to be at risk
of preterm birth (such as preterm labour, hypertensive
disease of pregnancy, antepartum haemorrhage, pre-
sence or absence of ruptured membranes at trial entry),
￿ the primary reason antenatal magnesium sulphate
treatment was given (such as neuroprotection of the
fetus, pre-eclampsia, or tocolysis),
￿ the number of babies in utero (singleton or
multiple),
￿ the gestational age when antenatal magnesium sul-
phate treatment was given,
￿ the time prior to birth antenatal magnesium sul-
phate treatment was given,
￿ the type, mode of administration and dosage of
antenatal magnesium sulphate planned and given,
￿ whether maintenance treatment with antenatal mag-
nesium sulphate was used, and
￿ whether repeat antenatal magnesium sulphate treat-
ment was used.
Methods/design
Study design
IPD meta-analysis.
Criteria for the studies for inclusion and exclusion
Studies, published or unpublished, will be considered
eligible if they randomised women considered at risk of
preterm birth (less than 37 weeks’ gestation) to either
magnesium sulphate or a suitable control treatment
with adequate allocation concealment. Trials will be
included if the primary aim of the study was to prevent
neurologic abnormalities in the unborn baby, or if the
primary aim was otherwise but long-term neurological
outcomes were reported for the infants. Quasi-random
study designs will be excluded. See Table 1 for a sum-
mary of the eligible trials as at September 2011.
Eligibility of trials will be assessed independently and
unblinded for author and journal by two members of
the AMICABLE IPD Project Team. Any differences in
opinion regarding eligibilityw i l lb er e s o l v e db yd i s c u s -
sion. If IPD are unavailable from any eligible trial, the
trial will be included in the review and aggregated and
stratified data will be used for sensitivity analyses were
possible.
Search strategy to identify potential trials
We will use the search strategy developed by the
Cochrane Pregnancy and Childbirth Review Group for
the Cochrane review, which identifies trials from:
1. quarterly searches of the Cochrane Central Register
of Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of
major conferences;
4. weekly current awareness alerts for a further 44
journals plus monthly BioMed Central email alerts.
We will also search CENTRAL, MEDLINE and
EMBASE to identify trials published since the search
cutoff date of 31 August 2008 for the Cochrane review;
using the terms [antenatal or prenatal] and [magnesium]
and [preterm or premature or neuroprotection or ‘cere-
bral palsy’].
In addition we will access Current Controlled Trials
http://www.controlled-trials.com and the Australian and
New Zealand Trials Register http://www.anzctr.org.au to
identify recently completed or ongoing trials.
Experts in the field and trialists will be asked if they
know of any unpublished or other trials.
Data collection and management
A new set of pre-specified and clearly defined variables
(both for participant-level and trial-level factors as well
as for outcomes) and a newly developed coding system
will be used. Data will be collected on all women rando-
mised coded for anonymity, (date of birth, centre identi-
fication); baseline data for descriptive purposes and
analyses (reason at risk of preterm birth, gestational age
at trial entry, plurality of the pregnancy, expected date
of delivery); details of the intervention given (date of
randomisation, allocated intervention, type and dose of
magnesium sulphate given, mode of administration,
whether maintenance dose given, whether re-treatment
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listed below to allow planned analyses.
Trialists will provide de-identified IPD in any conveni-
ent format by encrypted, electronic transfer where possi-
ble or other means as needed. The individual trial data
will be recoded as required and stored in a custom
designed secure database which will be only accessible
by authorised personnel of the AMICABLE Data Man-
agement Group. Trialists will be asked to verify all
recoded data prior to any analysis and the data will not
be used for any other purpose without permission of all
collaborators.
Data will be checked with respect to range, internal
consistency, missing or extreme values, errors and con-
sistency with published reports. Trial details such as
randomisation methods and intervention details will be
cross-checked against published reports, trial protocols
and data collection sheets. Inconsistencies or missing
data will be discussed with the individual trialists and
attempts will be made to resolve any problems by con-
sensus. Each trial will be analysed individually, and the
resulting analyses and trial data will be sent to the trial-
ists for verification.
We will assess risk of bias for each study using the
criteria outlined in the Cochrane Handbook for Systema-
tic Reviews of Interventions[47]. These criteria are:
1. Random sequence generation (checking for possible
selection bias)
2. Allocation concealment (checking for possible selec-
tion bias)
3. i. Blinding of participants and personnel (checking
for possible performance bias)
ii. Blinding of outcome assessment (checking for
possible detection bias)
4. Incomplete outcome data (checking for possible
attrition bias due to the amount, nature and handling of
incomplete outcome data)
5. Selective reporting (checking for reporting bias)
6. Other bias (checking for bias due to problems not
covered by 1 to 5 above)
We will make explicit judgements about whether stu-
dies are at high, low or unclear risk of bias, according to
t h ec r i t e r i ag i v e ni nt h eH a n d b o o k ;a n dw ew i l la s s e s s
the likely magnitude and direction of the bias and
w h e t h e rw ec o n s i d e ri ti sl i k e l yt oi m p a c to nt h e
findings.
Data items to be collected
Trial level information
1. Dates the trial opened and closed accrual
2. Number of women randomised
3. Informed consent procedures
4. Methods of random allocation
5. Stratification factors used
6. Methods of allocation concealment
7. Blinding of outcome assessment
8. Purpose magnesium sulphate treatment given (neu-
roprotection for the fetus, neuroprotection for the
mother, tocolysis, pre-eclampsia, other)
9. Details of the planned intervention in the experi-
mental arm
10. Details of the planned intervention in the control
arm
Participant-level information: maternal characteristics at
trial entry
1. Unique identification coded for anonymity
2. Maternal age
3. Parity
4. Ethnicity
5. Public or private patient
6. Previous obstetric history
7. Reason the woman was considered to be at risk of
preterm birth (such as preterm labour/pre-eclampsia/
placenta abruption/placenta previa/chorioamnionitis/
other antepartum haemorrhage/preterm rupture of
membranes)
8. Number of babies in-utero (singleton, twin or
higher order multiple pregnancy)
9. Gestational age at trial entry
Participant-level information: maternal outcomes after trial
entry
1. Actual treatment dose details (loading dose given,
maintenance dose, retreatment dose)
2. Time from antenatal magnesium sulphate treatment
to birth
3. Adverse events for the woman at time of treatment
4. Intrapartum information
5. Postnatal information
Participant-level information: infant outcomes
1. Unique baby identification and mother identifica-
tion coded for anonymity
2. Date and time of birth
3. Gestational age at birth
4. Gender
5. Mode of birth
6. Birth weight, length, head circumference
7. Apgar score at 1 and 5 minutes
8. Neonatal complications/status
9. Mortality and age at death
10. Cause of death
11. Childhood follow-up assessments
Planned analyses
A detailed statistical analysis plan will be prepared by
the AMICABLE Data Management Group and agreed
upon by the AMICABLE IPD Project Team and the
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lyses conducted will be based on the checked and
updated IPD from all available trials. All randomised
participants with outcome data available will be included
in the analyses, which will be performed on an intention
to treat basis, according to the treatment allocation at
randomisation.
For each of the outcomes a one stage approach to
analysis will be taken so that the IPD from all eligible
trials are included in a single model. Fitting a single
model for each outcome variable will enable the varia-
tion across trials to be accounted for within the model.
A treatment by trial interaction term will be tested to
assess heterogeneity of treatment effect across trials. If
excessive statistical heterogeneity in treatment effect or
inconsistency across trials is detected (i.e. if the trial by
treatment interaction term is significant), then the ratio-
nale for combining trials will be questioned and the
source of heterogeneity explored.
Binary outcomes will be analysed using log binomial
regression models and results will be presented as RR with
95% CI and associated two-sided p values. Continuous
outcomes will be analysed using linear regression models
and results will be presented as differences in means with
95% CI and two-sided p values. Correlation between out-
comes due to multiple births will be taken into account
using generalized estimating equations as appropriate.
Any differences in treatment effect between prespeci-
fied subgroups will be assessed by testing a treatment by
subgroup interaction term within the model.
Where data are missing, those patients will be
removed from the analysis. Reasons for missingness will
be explored where possible. For each outcome if there
are unbalanced or large amounts of missing endpoint
data for at least one trial then sensitivity analyses will be
undertaken to assess the impact of removing such trials
from the analysis.
Outcomes
Outcomes have been chosen to be most representative
of the clinically important measures of effectiveness and
safety, including serious outcomes, for women and their
babies.
1. Primary Outcomes
For the infants/children
￿death or cerebral palsy
For the women
￿any severe maternal outcome potentially related to
treatment (death, respiratory arrest or cardiac arrest)
2. Secondary Outcomes
For the infants
￿gestational age at birth
￿birth weight (raw values and Z scores) [48]
￿head circumference at birth (raw values and Z
scores) [48]
￿length at birth (raw values and Z scores) [48]
￿Apgar score less than 7 at five minutes
￿use of active resuscitation at birth
￿use of ongoing respiratory support
￿chronic lung disease/bronchopulmonary dysplasia
(as defined by trialists)
￿neonatal convulsions
￿neonatal encephalopathy
￿any IVH
￿severe IVH (grade 3 or 4)
￿cystic periventricular leukomalacia
￿posthaemorrhagic hydrocephaly or ventriculomegaly
￿proven systemic neonatal infection
￿necrotising enterocolitis
￿patent ductus arteriosus requiring treatment
￿retinopathy of prematurity
For the children (follow up)
￿death (fetal, neonatal or later death up to the time
of follow up) and cause of death
￿cerebral palsy (any cerebral palsy, as defined by the
trialists)
￿severity of cerebral palsy (categorised as, mild, mod-
erate or severe, as defined by the trialists)
￿severe adverse neonatal outcome (defined as death,
chronic lung disease, patent ductus arteriosus requir-
ing treatment, neonatal encephalopathy, necrotising
enterocolitis, stage 3 or worse retinopathy of prema-
turity, grade 3 or 4 IVH)
￿other neurosensory impairments (other than cere-
bral palsy)
○developmental delay or intellectual impairment
(categorised as nil, mild, moderate or severe, by
the trialists)
○blindness (defined as visual acuity worse than
6/60 (20/200) in the better eye)
○deafness (defined as hearing loss requiring
amplification or worse)
○gross motor dysfunction (defined as mild, mod-
erate or severe, by trialists or by the Gross
Motor Classification System [score 1-5], if avail-
able) [49]
○psychomotor dysfunction (categorised as nil,
mild (less than 85), moderate (less than 70) or
severe (less than 55) by the Psychomotor
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of Infant Development [50]
￿any neurosensory disability (defined as developmen-
tal delay or intellectual impairment [developmental
quotient or intelligence quotient more than one SD
below the mean], cerebral palsy [abnormality of
muscle tone with motor dysfunction], blindness,o r
deafness, at follow up later in childhood)
￿major neurosensory disability (defined as any mod-
erate or severe neurosensory impairment)
￿death or substantial gross motor dysfunction
(defined as death, or motor dysfunction (such that
the child was not walking at age two years or later,
or the inability to grasp and release a small block
with both hands at two years or later))
￿death or neurosensory disability (defined as death
or any of the neurosensory impairments)
￿death or major neurosensory disability (defined as
death or any moderate or severe neurosensory
impairment)
￿growth assessments at childhood follow up for:
○weight (raw values and Z scores) [51]
○head circumference (raw values and Z scores)
[51]
○height (raw values and Z scores) [51]
￿other developmental assessments (as used by the
trialists)
For the women
￿adverse effects severe enough to stop treatment
￿postpartum haemorrhage
￿mode of birth
￿chorioamnionitis during labour
￿intrapartum fever requiring the use of antibiotics
￿length of postnatal stay
￿individual components of maternal primary outcome
3. Planned subgroup analyses
Where data exist, subgroup comparisons will be con-
ducted for the following outcomes;
￿death or cerebral palsy
￿death
￿cerebral palsy
￿severe maternal adverse event potentially related to
treatment
￿death or major neurosensory disability
Any differences in treatment effect between subgroups
will be assessed by testing a treatment by subgroup
interaction term within the model.
Subgroups
1) primary reason pregnancy was considered to be at
high risk of preterm delivery (preterm labour/pre-
eclampsia/placenta abruption/placenta previa/chor-
ioamnionitis/other antepartum haemorrhage/prela-
bour rupture of the membranes)
2) purpose of treatment - neuroprotection of the
fetus/neuroprotection of the mother/pre-eclampsia/
eclampsia/tocolysis/other)
3) multiple birth
4) gestational age when antenatal magnesium sul-
phate treatment was given
a) categories: < 26; 26 to < 28; 28 to < 30; 30 to
< 32; 32 to < 34 completed weeks at randomisa-
tion; (groups will be combined if data are
insufficient);
b) categories: < 34; ≥ 34 completed weeks at
randomisation;
c) categories: < 32; ≥ 32 completed weeks at
randomisation;
d) categories: < 30; ≥ 30 completed weeks at
randomisation;
e) categories: < 28; ≥ 28 completed weeks at
randomisation.
5) time from antenatal magnesium sulphate treat-
ment to birth (0 to < 4 hours; 4 to < 8 hours; 8 to <
12 hours; 12 to < 24 hours (groups will be combined
if data are insufficient)
6) mode of administration (intravenous,
intramuscular)
7) actual dose of antenatal magnesium sulphate
received
a) actual total trial dose received (< 4 g; 4 to <
14 g; 14 to < 28 g; ≥ 28 g);
b) actual total trial dose received adjusted for
pre-trial dose received (< 4 g; 4 to < 6 g; 6 to <
14 g; 14 to < 28 g; ≥ 28 g);
c) pre-trial dose received or not
8) whether maintenance treatment with antenatal
magnesium sulphate was used
9) whether repeat antenatal magnesium sulphate
treatment was used
4. Planned sensitivity analyses
To assess whether the results are robust to trial design,
sensitivity analyses will be performed by excluding trials
with high rates of participant exclusions, where losses
are considered to have the potential to impact on the
results.
To assess whether the results are robust to the inclu-
sion or exclusion of trials where IPD are unavailable
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combined with available aggregate data from such trials.
5. Multiple comparisons
A large number of outcomes are being investigated in
this study which increases the chance of observing ‘false
positive’ results. However, all outcomes are important in
giving a full clinical picture that considers the benefits
and risks to both mothers and infants. We do not plan
formal statistical adjustment of p values planned to
account for multiple comparisons due to the non-inde-
pendence of outcomes in this study. Results will be
interpreted with caution.
Ethics and management issues
Ethical considerations
Participants in the individual trials have previously given
informed consent to participate in their respective trial.
The data for this project are to be used for the purpose
for which they were originally collected and are available
through an agreement between all trialists of the colla-
borative group. These trialists remain custodians of their
original individual trial data at all times.
Project management
For the purpose of this project, an international Colla-
borative Group, The AMICABLE Group, was formed
and consists of the following working groups with speci-
fic responsibilities and tasks:
1. The AMICABLE IPD Project Team
The AMICABLE IPD Project Team is the Steering
Group which is responsible for the project’s manage-
ment decisions and the daily management of the
Collaboration. The Project Team’st a s k sa r et o
design the project’s protocol and analysis plan, orga-
nise The AMICABLE Group Meetings and act as a
liaison between all the members of The AMICABLE
Group. The AMICABLE IPD Project Team will
m e e tr e g u l a r l ye v e r yt w ot of o u rm o n t h s ,u s u a l l yb y
teleconference.
2. The AMICABLE Trialist Group
The AMICABLE Group will consist normally of two
members from each eligible trial. The first author
for each trial, will be invited to become a member of
the Collaboration. In order to keep The AMICABLE
Group updated, authors of new trials or previously
unknown trials may be contacted and invited to join
the Collaboration in the course of the project.
3. AMICABLE Data Management Group
The data management group will be convened by the
Chair of The AMICABLE IPD Project Team and com-
prises the statisticians from the data management centre
and participating trials who will conduct the analyses.
The data management group will be responsible for the
storage and analyses of the IPD project data.
AMICABLE Group Meetings
The AMICABLE Group face-to-face meetings will be
organised at least twice during the study. Representa-
tives of all eligible trials will be invited to attend the
meetings. The meetings will be scheduled, if possible, in
conjunction with international conferences. During
those meetings, various aspects of the project will be
discussed with all the collaborators, such the project’s
design and conduct, the analysis plan, and the interpre-
tation and reporting of the results. The final collabora-
tors’ meeting is scheduled for late 2012.
Publication of results
The final results of the study will be presented to the
collaborators for discussion. The main manuscript will
be prepared by The AMICABLE IPD Project Team and
circulated to The AMICABLE Group and The AMIC-
ABLE Data Management Group for comment and revi-
sion. The revised draft paper will be circulated for final
comment and agreement prior to publication. Publica-
tions will be authored in the name of The AMICABLE
Group. The names of all participating collaborators will
be acknowledged within the manuscript.
Discussion
Babies born preterm compared with those born at term
h a v eah i g h e rc h a n c eo fd y i n gi nt h ef i r s tf e ww e e k so f
life. Babies who survive have a high risk of substantial
disability from neurosensory impairments such as cere-
bral palsy, blindness, deafness, or cognitive dysfunction.
The Cochrane review on antenatal magnesium sul-
phate given to women at risk of preterm birth has iden-
tified an important reduction in the risk of cerebral
palsy. However it remains unclear what the role of
antenatal magnesium sulphate is in clinical practice.
This IPD meta-analysis, using data already collected in
the individual trials may reveal which women and/or
babies might benefit more from antenatal magnesium
sulphate. This approach has been described as the ‘gold
standard’ of systematic review methodology as it allows
for more powerful and flexible analysis of both subgroups
and outcomes. The international collaboration of trialists
will guarantee exceptional data availability and quality,
and ensure endorsement and global implementation of
recommendations into clinical practice and policy.
The AMICABLE Group was formed in 2009 to under-
take a meta-analysis based on IPD. Provision of data by
Systematic Reviews 2012, 1:21
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Page 8 of 10the participating collaborators commenced in 2010 and
results will be ready for presentation in 2012.
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